Lydus Medical

Company Overview

Snapshot

Founded in June 2017 by Kamall Daas, Muhammad Mansour, and Dean Ad El, Lydus Medical operates with 1–10 employees. The company has raised $2.7 million across two funding rounds from six investors, with Sanara Ventures participating. In January 2023, Lydus Medical announced that its Vesseal device received FDA 510(k) clearance.

Business overview

Lydus Medical is a Health Tech & Life Sciences company developing a novel system for automating microvascular anastomoses. Its core product, Vesseal, is an automated microvascular suturing device designed to provide standardized, thread-only, omni-vessel anastomoses. This technology aims to simplify and accelerate procedures while enhancing safety and effectiveness in various surgical fields, including breast reconstruction and vascular access for hemodialysis. The company operates within the Medical Devices sector, specifically focusing on Medical Treatment & Therapeutics, and serves healthcare providers.

Strategic signal

In January 2023, Lydus Medical announced the US FDA 510(k) clearance for its Vesseal microvascular anastomosis aid device. This regulatory approval is a significant validation of the company's technology, signaling its readiness for market entry and potential to address critical unmet clinical needs in complex microvascular surgeries. For investors, this milestone indicates a de-risked pathway to commercialization and potential for rapid adoption in the medical device market, positioning Lydus Medical for substantial growth.

Company Intelligence Q&A

What is Lydus Medical's primary product?

Lydus Medical's primary product is Vesseal, an automated microvascular suturing device designed to create small blood vessel anastomoses simply, quickly, safely, and effectively.

When did Lydus Medical receive FDA clearance for its device?

In January 2023, Lydus Medical announced that its Vesseal device received FDA 510(k) clearance, allowing it to address unmet clinical needs in various surgical fields.

What was the purpose of the May 2021 funding round?

In May 2021, Lydus Medical secured $2.7 million in Pre-A funding from investors including. This capital was intended to accelerate FDA clearance, scale product development, and prepare for market entry.

Who are the founders of Lydus Medical?

Lydus Medical was founded by Kamall Daas, Muhammad Mansour, and Dean Ad El.

What problem does Lydus Medical's technology aim to solve?

Lydus Medical's Vesseal device aims to automate and standardize the creation of small blood vessel anastomoses, addressing the challenges of complex manual microvascular surgeries by improving consistency, shortening operation time, and enhancing clinical outcomes.